AFT1 Antibody

What is AFT1 and why is it important in research?

AFT1 (Activating Transcription Factor 1) is a transcription factor with well-established roles in iron homeostasis regulation through transcriptional induction of iron-regulon genes . Recent studies have expanded understanding of AFT1's functions beyond iron regulation, revealing its critical involvement in chromosome stability and interactions with kinetochore proteins .

AFT1 responds to iron starvation by translocating to the nucleus and activating target genes . Additionally, AFT1 associates with the kinetochore complex through direct interaction with the Iml3 protein, contributing to proper chromosome segregation during meiosis . These dual functions make AFT1 an important research target for understanding both iron homeostasis mechanisms and fundamental aspects of chromosome biology.

Research involving AFT1 antibodies can provide valuable insights into cellular iron sensing, transcriptional regulation, and the mechanisms governing faithful chromosome transmission during cell division.

What sample types are compatible with AFT1 antibodies?

AFT1 antibodies have been validated for use with multiple sample types, with compatibility varying based on the specific antibody formulation and application. Common compatible sample types include:

• Cell culture cells (adherent and suspension cells with protocol modifications)

• Yeast whole cell extracts for studying native AFT1

• Formaldehyde cross-linked chromatin samples for ChIP experiments

• Nuclear and cytoplasmic fractions for studying AFT1 localization

When working with cell culture applications, cell density should be optimized based on AFT1 expression levels, cell size, and treatment conditions. For optimal results with adherent cells, plates should be approximately 75-90% confluent . For suspension cells, additional preparation steps are required, including coating plates with Poly-L-Lysine (10 μg/mL) for 30 minutes at 37°C before cell seeding, and using 8% formaldehyde as the fixative agent .

For yeast samples, which have been extensively used in fundamental AFT1 research, protocols typically involve spheroplasting followed by gentle lysis to preserve protein-protein interactions for co-immunoprecipitation studies .

What are the best methods for validating AFT1 antibody specificity?

Validating AFT1 antibody specificity is crucial for generating reliable research data. Multiple complementary approaches are recommended:

• Western blot verification: A high-quality AFT1 antibody should detect a single protein band of the expected molecular weight. This band should be blockable by the synthesized immunogen peptide, confirming specificity .

• Genetic controls: Utilize AFT1 knockout/deletion strains (Δaft1) as negative controls in experiments to confirm antibody specificity . The absence of signal in these genetic backgrounds provides strong evidence for antibody specificity.

• Tagged protein controls: Compare antibody detection with epitope-tagged versions of AFT1 (e.g., AFT1-TAP). Research has confirmed that properly tagged AFT1 maintains normal function and regulation of target genes .

• Cross-reactivity assessment: When using antibodies across species, verify specificity by testing against lysates from multiple organisms. For example, some commercial AFT1 antibodies have been validated against human, mouse, and rat samples .

• Immunoprecipitation followed by mass spectrometry: For highest confidence validation, immunoprecipitate AFT1 and verify its identity through mass spectrometry, which can also reveal interacting partners.

What are common applications for AFT1 antibodies in research?

AFT1 antibodies have versatile applications in multiple research methodologies:

• Western blotting: For detecting AFT1 protein levels and post-translational modifications in various experimental conditions, particularly when studying iron-responsive regulation .

• Chromatin Immunoprecipitation (ChIP): AFT1 antibodies have been successfully used in ChIP experiments to study binding to target promoters like FET3 under varying iron conditions .

• Co-immunoprecipitation (Co-IP): For studying protein-protein interactions, such as the interaction between AFT1 and kinetochore proteins (Iml3, Ctf19, Chl4) or with Grx3p under different iron conditions .

• Immunofluorescence microscopy: To track AFT1 subcellular localization in response to iron availability or other experimental conditions .

• ELISA-based detection: Cell-based ELISA methods provide quantitative assessment of AFT1 protein levels in adherent or suspension cell cultures .

For cell-based ELISA applications, antibodies can detect AFT1 expression in as few as 5,000 cells, offering a sensitive method for quantifying protein levels without the need for cell lysis .

How can AFT1 antibodies be used to study iron-dependent nuclear localization?

AFT1 antibodies are valuable tools for investigating the mechanisms of iron-dependent nuclear localization through several specialized approaches:

• Subcellular fractionation with immunoblotting: This approach allows quantitative assessment of AFT1 distribution between nuclear and cytoplasmic compartments in response to iron availability. Researchers have used this method to demonstrate that under iron starvation, AFT1 accumulates in the nucleus, whereas iron repletion triggers nuclear export .

• Immunofluorescence microscopy: Using AFT1 antibodies for immunofluorescence enables direct visualization of AFT1 localization. This technique has been instrumental in studying how mutations in specific residues (Leu99, Leu102, Ser210, Ser224, Cys291, Cys293, Thr421, Thr423, Thr431, and Thr435) affect iron-responsive nuclear export .

• Live-cell imaging with fluorescently-tagged AFT1: Though not directly using antibodies, this complementary approach validates antibody-based findings. GFP-tagged AFT1 constructs can be used alongside antibody-based methods to track dynamic changes in localization.

Research has demonstrated that proper AFT1 nuclear localization in response to iron starvation requires not only iron sensing but also intact sphingolipid biosynthesis pathways . Using AFT1 antibodies, researchers determined that treatment with N-acetylcysteine (NAC) did not affect AFT1 localization in iron-depleted ypk1 mutants, indicating that oxidative stress was not the cause of mislocalization .

To definitively study iron-dependent localization, researchers can combine AFT1 antibodies with mutant strains defective in specific signaling pathways. For example, in cells expressing mutant AFT1 proteins [AFT1(LA), AFT1(CA), AFT1(SA), or AFT1(TA)], antibody-based approaches revealed distinct localization patterns despite all mutants remaining nuclear regardless of iron status .

What are the optimal conditions for using AFT1 antibodies in chromatin immunoprecipitation (ChIP) experiments?

AFT1 antibodies have been successfully used in ChIP experiments to study its dynamic binding to target promoters under varying iron conditions. Optimization includes:

• Crosslinking conditions: Effective ChIP protocols for AFT1 typically use formaldehyde (1%) for crosslinking protein-DNA complexes, with 10-15 minutes of incubation at room temperature being optimal .

• Sonication parameters: Chromatin should be sheared to fragments of approximately 200-500bp, which typically requires 8-12 sonication cycles (30 seconds on/30 seconds off) at medium power.

• Antibody selection and amount: For ChIP applications, antibodies recognizing native protein rather than denatured epitopes are preferred. Use 2-5 μg of AFT1 antibody per ChIP reaction with 1-2×10⁷ yeast cells .

• Control selection: Include the following controls:

  • Input DNA (pre-immunoprecipitation)

  • No-antibody control

  • Non-specific IgG control

  • Δaft1 strain as a negative control

  • Positive control locus (e.g., FET3 promoter)

  • Negative control region (non-AFT1 binding site)

• Detection method: Quantitative PCR (qPCR) has been used successfully to measure AFT1 binding to target promoters, with research showing that AFT1 binds to the FET3 promoter only under iron-limited conditions in wild-type cells .

How can researchers use AFT1 antibodies to investigate its role in chromosome stability?

AFT1 antibodies can be instrumental in investigating AFT1's role in chromosome stability through several specialized approaches:

• Co-immunoprecipitation with kinetochore components: AFT1 antibodies have been used successfully to co-immunoprecipitate kinetochore proteins, revealing that AFT1 interacts specifically with Iml3, a component of the kinetochore COMA complex . The interaction network can be mapped by performing co-IPs in various mutant backgrounds (e.g., ctf19Δ, chl4Δ, iml3Δ) .

• ChIP-qPCR for cohesin enrichment: AFT1 antibodies can be used in conjunction with cohesin subunit antibodies (e.g., Scc1-HA) to study how AFT1 contributes to cohesin association with pericentromeric regions. Research has demonstrated that aft1Δ mutants, like iml3Δ mutants, show reduced Scc1 enrichment at pericentromeric and centromeric regions but normal levels along chromosomal arms .

• Chromosome spreads with immunofluorescence: This technique allows visualization of AFT1 localization relative to kinetochore proteins on spread chromosomes, providing spatial information about their association.

Research demonstrated that AFT1, like Iml3, is required for proper chromosome segregation during meiosis . Studies using GFP-labeled chromosomes showed that aft1Δ mutants display a chromosome segregation pattern similar to iml3Δ mutants after meiosis, with approximately 35% of cells showing abnormal segregation patterns (GFP dots in fewer than four spores) .

The table below summarizes the chromosome segregation defects observed in wild-type versus aft1Δ mutants:

This role in chromosome stability appears to be independent of AFT1's function in iron homeostasis, representing an important area for further research using AFT1 antibodies .

What are the key considerations when using AFT1 antibodies to study protein-protein interactions?

When using AFT1 antibodies to study protein-protein interactions, researchers should consider several important factors:

The iron status of cells significantly affects AFT1's interaction network. Under iron-replete conditions, AFT1 interacts with Grx3p, but this interaction is lost in Atm1p-depleted cells . This finding, coupled with reduced 55Fe binding to Grx3p in Atm1p-depleted cells, suggests that iron-sulfur cluster loading by Grx3p is a prerequisite for its interaction with AFT1 .

How can AFT1 antibodies be used to investigate the relationship between iron regulation and sphingolipid biosynthesis?

Recent research has revealed an unexpected connection between sphingolipid biosynthesis and AFT1-mediated iron regulation, providing an exciting new area where AFT1 antibodies can be applied:

• Nuclear translocation assays: AFT1 antibodies can be used in immunofluorescence or subcellular fractionation studies to track how disruptions in sphingolipid biosynthesis affect AFT1 nuclear localization in response to iron starvation .

• Target gene expression correlation: Combining AFT1 antibodies for ChIP with gene expression analysis allows researchers to correlate AFT1 binding to target promoters with transcriptional outcomes when sphingolipid pathways are perturbed .

• Pathway inhibitor studies: AFT1 antibodies can be used to monitor AFT1 localization and function when cells are treated with sphingolipid pathway inhibitors such as Aureobasidin A, or when supplemented with pathway intermediates like dihydrosphingosine (DHS) .

Research has demonstrated that AFT1 nuclear localization and transcriptional response to iron starvation require biosynthesis of sphingolipids . In ypk1 mutant cells, which have defects in sphingolipid biosynthesis, AFT1 fails to properly localize to the nucleus in response to iron starvation .

These findings suggest an integrative model where the TORC2-YPK1 signaling pathway, which regulates sphingolipid synthesis, converges with iron signaling to control AFT1 function . AFT1 antibodies provide powerful tools to dissect this regulatory network by allowing researchers to track AFT1 localization, target binding, and protein interactions under conditions where either pathway is perturbed.

What are common troubleshooting strategies for AFT1 antibody applications?

When working with AFT1 antibodies, researchers may encounter several technical challenges. Here are effective troubleshooting strategies for common issues:

• High background in immunofluorescence or Western blots:

  • Increase blocking time or concentration (5% BSA or milk is typically effective)

  • Optimize antibody dilution through titration experiments

  • Include additional wash steps with increased detergent concentration

  • Test alternative blocking reagents (BSA vs. milk vs. commercial blockers)

  • Use highly purified antibody preparations when available

• Weak or no signal in Western blots:

  • Ensure adequate protein loading (AFT1 may be low abundance in some cell types)

  • Optimize transfer conditions for high molecular weight proteins

  • Test different membrane types (PVDF vs. nitrocellulose)

  • Verify sample preparation maintains protein integrity (use fresh protease inhibitors)

  • Consider antigen retrieval methods if epitope accessibility is an issue

• Poor immunoprecipitation efficiency:

  • Optimize antibody-to-lysate ratio

  • Increase incubation time (overnight at 4°C often improves results)

  • Test different bead types (Protein A vs. Protein G vs. directly conjugated)

  • Use gentler lysis conditions to preserve protein complexes

  • Pre-clear lysates to reduce non-specific binding

• Inconsistent ChIP results:

  • Standardize crosslinking conditions (time, temperature, formaldehyde concentration)

  • Optimize sonication parameters for consistent fragment size

  • Ensure cells are in the appropriate condition (iron-deprived for maximum AFT1 binding)

  • Include positive control regions known to bind AFT1 (FET3 promoter) and negative controls

  • Consider cell synchronization, as AFT1 binding may vary with cell cycle stage

How should researchers optimize AFT1 antibody dilutions for different applications?

Optimizing antibody dilutions is critical for achieving high-quality results while conserving valuable reagents. Different applications require distinct optimization approaches:

• Western blotting optimization:

  • Starting range: 1:500 to 1:2000 dilution

  • Perform titration experiments using a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Assess signal-to-noise ratio at each dilution

  • Consider the detection method (ECL vs. fluorescence) when optimizing

  • For fluorescent detection systems, lower antibody concentrations often yield better results

• Immunofluorescence optimization:

  • Starting range: 1:100 to 1:500 dilution

  • Include negative controls (secondary-only, non-specific IgG)

  • Evaluate both signal intensity and background at each dilution

  • Consider cell type and fixation method when optimizing

  • AFT1 antibodies should localize to the nucleus under low-iron conditions

• ChIP optimization:

  • Starting amount: 2-5 μg antibody per reaction

  • Test different antibody amounts while keeping cell number constant

  • Measure enrichment at known AFT1 binding sites (e.g., FET3 promoter)

  • Compare enrichment ratios (target/control region) rather than absolute signals

  • Include a non-specific IgG control at the highest antibody concentration tested

• ELISA optimization:

  • Follow manufacturer's recommended starting dilution (typically 1:1000 to 1:2000)

  • Prepare standard curves using purified antigen when available

  • Test dilutions in duplicate or triplicate to assess reproducibility

  • Determine the linear range of detection for your sample type

  • For cell-based ELISA, optimize cell number (typically 30,000 HeLa cells per well, with detection possible in as few as 5,000 cells)

When working with new antibody preparations or different experimental conditions, full optimization should be repeated to ensure optimal results.

How do experimental conditions affect AFT1 antibody specificity and performance?

Various experimental conditions can significantly impact AFT1 antibody performance, requiring careful optimization for each research context:

• Iron availability effects:

  • Iron status dramatically alters AFT1 localization and complex formation

  • Under iron-replete conditions, AFT1 may redistribute from the nucleus to the cytoplasm

  • Iron availability affects AFT1 binding to target promoters, potentially influencing epitope accessibility

  • Consider standardizing iron conditions for consistent results

• Cell fixation considerations:

  • For immunofluorescence or ChIP applications, fixation method impacts epitope preservation

  • Paraformaldehyde (4%) is typically effective for preserving AFT1 structure

  • For suspension cells in ELISA applications, 8% formaldehyde may be required

  • Methanol fixation may expose different epitopes than formaldehyde fixation

• Buffer composition impact:

  • Lysis buffer composition critically affects antibody performance

  • For co-immunoprecipitation studies, use buffers that preserve protein-protein interactions

  • Detergent type and concentration should be optimized (typically 0.1-1% NP-40 or Triton X-100)

  • Salt concentration affects specificity (150-300mM NaCl range is typical)

  • Include protease inhibitors to prevent epitope degradation

• Detection system considerations:

  • Secondary antibody selection should match the host species of the primary antibody

  • Signal amplification methods (e.g., tyramide signal amplification) may be needed for low-abundance targets

  • When multiplexing, consider antibody cross-reactivity and spectral overlap

Research has shown that AFT1 forms different protein complexes depending on iron status. Under iron-replete conditions, AFT1 interacts with Grx3p , while under iron limitation, it associates with DNA at target promoters like FET3 . These different complex formations may affect epitope accessibility and antibody binding efficiency.

Additionally, mutations in specific amino acid residues of AFT1 (Leu99, Leu102, Cys291, Cys293) affect its interaction with target promoters , which may indirectly impact antibody binding or immunoprecipitation efficiency in mutant backgrounds.

How might new antibody technologies advance AFT1 research?

Emerging antibody technologies offer exciting opportunities to advance AFT1 research beyond current capabilities:

• Single-domain antibodies (nanobodies): These smaller antibody fragments derived from camelid antibodies offer advantages for studying AFT1:

  • Better penetration into nuclear compartments for improved immunofluorescence

  • Potential for live-cell imaging of AFT1 dynamics

  • Greater epitope accessibility in complex formations

  • Reduced background in ChIP experiments

• Proximity labeling with antibody-enzyme fusions: AFT1 antibodies conjugated to enzymes like BioID or APEX2 would enable:

  • Identification of proteins in close proximity to AFT1 under different iron conditions

  • Mapping the complete AFT1 interactome at specific cellular locations

  • Detecting transient interactions that may be missed by conventional co-IP

• Bi-specific antibodies for studying complex formation: These could simultaneously target AFT1 and potential interaction partners to:

  • Confirm direct protein-protein interactions in situ

  • Study the dynamics of complex formation in response to iron availability

  • Investigate the spatial relationship between AFT1 and kinetochore components

• Conformation-specific antibodies: Developing antibodies that specifically recognize iron-bound versus iron-free conformations of AFT1 would:

  • Provide direct measurement of AFT1 activation state

  • Allow quantification of active versus inactive AFT1 pools

  • Help elucidate the structural changes induced by iron binding

• Degradation-targeting chimeric antibodies: These could be used to:

  • Achieve rapid, specific depletion of AFT1 to study acute effects

  • Target specific AFT1 complexes for degradation to dissect functional roles

  • Create chemical genetic systems for temporal control of AFT1 function

These technologies could help resolve open questions, such as how AFT1 integrates signals from iron availability and sphingolipid biosynthesis , or the precise mechanism by which AFT1 contributes to chromosome stability independent of its iron regulatory function .

What are the emerging research questions where AFT1 antibodies will be critical?

Several frontier research areas will depend heavily on high-quality AFT1 antibodies:

• Integration of metabolic and chromosome stability pathways:

  • How does AFT1's dual role in iron homeostasis and chromosome stability allow cells to coordinate these processes?

  • Are there conditions where these functions are differentially regulated?

  • Do post-translational modifications of AFT1 direct its activity toward one function versus another?

• Sphingolipid-iron regulatory network mapping:

  • Recent research has revealed unexpected connections between sphingolipid biosynthesis and AFT1-mediated iron regulation

  • What are the molecular mechanisms linking these pathways?

  • Does AFT1 interact directly with sphingolipid pathway components?

  • How do iron and sphingolipid signals converge on AFT1?

• Structural biology of AFT1 complexes:

  • What structural changes occur when AFT1 binds iron?

  • How does AFT1 structurally interact with kinetochore components like Iml3 ?

  • Could antibodies be used to stabilize AFT1 complexes for structural studies?

• Single-cell variation in AFT1 activity:

  • Do individual cells in a population show heterogeneity in AFT1 activation?

  • How does cell cycle position affect AFT1 activity and localization?

  • Can antibody-based imaging reveal the dynamics of AFT1 activation at the single-cell level?

• Therapeutic targeting of AFT1 pathways:

  • Could antibodies or derived molecules be developed to modulate AFT1 function?

  • Are there disease contexts where AFT1 pathway modulation would be beneficial?

  • How can our understanding of AFT1 in model organisms inform therapeutic approaches?

Research has shown that AFT1's interaction with the kinetochore protein Iml3 is critical for its role in promoting pericentromeric cohesin . AFT1 antibodies will be essential tools for investigating whether this interaction is regulated by iron availability or other cellular signals, potentially revealing how cells coordinate metabolic status with chromosome dynamics.

Similarly, the discovery that sphingolipid biosynthesis is required for proper AFT1 nuclear localization and transcriptional response to iron starvation opens exciting research directions . AFT1 antibodies will be crucial for mapping how these signaling pathways intersect at the molecular level.